ANI Pharmaceuticals, Inc.
NASDAQ:ANIPDrug Manufacturers - Specialty & Generic
-$1.42 today
- Market cap
- $1.62B
- Beta
- 0.44
- P/E (TTM)
- 18.5
- EPS (TTM)
- $4.29
Volume 0.29M
Average 0.35M
ANIP Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
ANI Pharmaceuticals, Inc.NASDAQ: ANIP
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation outflow shrinks to $0
Q1 FY2026 stock-based compensation was $0, compared with $8.87M a year earlier. Trailing-twelve-month stock-based compensation was $29.06M. Over 3 fiscal years it compounded at +37.5% a year.
Context
- Stock-based compensation amounted to 4.3% of revenue in FY2025, down 0.5 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $7.27M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 37.93M USD
- Year-over-year change
- +29.3%
- 4-year CAGR
- +37.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 37.93M | +29.3% |
| FY2024 | 2024-12-31 | 29.34M | +42.1% |
| FY2023 | 2023-12-31 | 20.65M | +41.5% |
| FY2022 | 2022-12-31 | 14.6M | +39.2% |
| FY2021 | 2021-12-31 | 10.49M | — |
Stock-Based Compensation vs competitors
How ANIP compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -7.1% is the 6th highest of 10, against a peer median of +9.7%.
- Stock-based compensation amounts to 3.1% of revenue for ANIP, versus a peer median of 2.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $172.3M USD | +9.7% | +15.1% | 1.2% | |
| LTM Jun 2026 | $168M USD | +24.4% | +8.2% | 1.0% | |
| LTM Jun 2026 | $149M USD | +12.9% | +19.7% | 1.4% | |
| LTM Sep 2026 | ₹117M INR | -72.7% | — | 0.0% | |
| LTM Mar 2026 | $41.26M USD | +13.2% | +22.4% | 5.2% | |
| LTM Mar 2026 | $29.06M USD | -7.1% | +37.5% | 3.1% | |
| LTM Mar 2026 | $28.16M USD | +10.9% | +15.2% | 3.9% | |
| LTM Jun 2026 | $26.81M USD | -10.2% | +0.1% | 0.9% | |
| LTM Mar 2026 | $19.89M USD | -13.9% | +24.1% | 6.6% | |
| LTM Mar 2026 | $11.78M USD | -34.6% | +16.2% | 4.4% | |
| LTM Mar 2026 | $5.91M USD | — | +57.3% | 4.4% | |
| Peer median (excluding ANIP) | — | +9.7% | +16.2% | 2.6% | |
Competitors are the stored peer set for ANIP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (42.6M) | (47.9M) | 18.78M | (18.52M) | 78.34M |
| Depreciation & Amortization | 47.25M | 59.65M | 59.79M | 67.73M | 91.42M |
| Deferred Income Tax | (16.75M) | (15.25M) | (11.74M) | (21.91M) | 14.24M |
| Stock-Based Compensation | 10.49M | 14.6M | 20.65M | 29.34M | 37.93M |
| Change in Working Capital | (84K) | (51.3M) | 24.86M | (11.19M) | (7.12M) |
| Accounts Receivables | (5.55M) | (36.91M) | 3.36M | (21.09M) | (58.53M) |
| Inventory | 3.22M | (23.63M) | (5.84M) | (21.29M) | (5.96M) |
| Accounts Payables | 10.17M | 5.04M | 7.55M | 479K | 15.16M |
| Other Working Capital | (7.93M) | 4.2M | 19.79M | 30.71M | 42.21M |
| Other Non-Cash Items | 5.02M | 8.99M | 6.62M | 18.56M | (29.57M) |
| Operating Cash Flow | 3.32M | (31.2M) | 118.96M | 64.02M | 185.23M |
| Capital Expenditures | (23.64M) | (16.46M) | (18.51M) | (16.95M) | (34.32M) |
| Acquisitions (Net) | (84.49M) | (33K) | 0 | (401.28M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (18.43M) | (6.83M) | (9.64M) | 12.8M | (20.49M) |
| Investing Cash Flow | (105.48M) | (15.74M) | (18.51M) | (404.72M) | (34.32M) |
| Debt Repayment | 99.02M | (3M) | (3M) | 345.22M | (10.16M) |
| Common Stock Issued | 69.58M | 0 | 80.56M | 0 | 13.6M |
| Common Stock Repurchased | (890K) | (1.96M) | (4.99M) | (10.96M) | (12.21M) |
| Dividends Paid | (190K) | (1.63M) | (1.63M) | (1.63M) | (1.16M) |
| Other Financing Activities | 2.07M | 1.46M | (3.5M) | (67.69M) | (26K) |
| Financing Cash Flow | 194.6M | (5.13M) | 67.44M | 264.95M | (9.94M) |
| Effect of Forex Changes | 0 | 0 | 0 | (470K) | (233K) |
| Net Change in Cash | 92.43M | (52.07M) | 167.89M | (76.23M) | 140.73M |
| Free Cash Flow | (20.32M) | (47.66M) | 100.45M | 47.06M | 150.9M |
ANI Pharmaceuticals, Inc.
NASDAQ:ANIP
Intrinsic Alpha fair value
Locked
Current Price
$71.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.